Vanda Pharmaceuticals (VNDA) Stock Analysis & AI Equity Report
Vanda Pharmaceuticals (VNDA) overview
Vanda Pharmaceuticals (VNDA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 216m and operating profit of USD -151m; the year-end share price was 8.82 USD and market capitalisation was USD 521m. Vanda Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Vanda Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Vanda Pharmaceuticals
Vanda Pharmaceuticals develops and commercializes medicines for patients with unmet medical needs. Its marketed products treat schizophrenia and bipolar I disorder, sleep disorders including Non-24 and Smith-Magenis syndrome, relapsing forms of multiple sclerosis, and motion-induced vomiting. The company also has drug candidates and potential additional indications in development for neurological, psychiatric, gastrointestinal, dermatological, ophthalmic, and blood disorders.
Generate the Vanda Pharmaceuticals report
Vanda Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Vanda Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Vanda Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.